Company Filing History:
Years Active: 2005
Title: Alyce Lynn Finelli: Innovator in Alzheimer's Research
Introduction
Alyce Lynn Finelli is a notable inventor based in Parsippany, NJ (US). She has made significant contributions to the field of Alzheimer's research through her innovative work. Her research focuses on the genetic factors associated with Alzheimer's Disease, particularly through the use of transgenic models.
Latest Patents
Alyce Lynn Finelli holds a patent for "Transgenic Drosophila melanogaster expressing a β42 in the eye." This patent discloses transgenic flies that exhibit altered phenotypes due to the expression of the Abeta and C99 portions of the human APP gene. The patent also outlines a method for identifying genes and their human homologs that may be involved in Alzheimer's Disease. Furthermore, it discusses the potential use of these human homologs as drug targets for developing therapeutics aimed at treating Alzheimer's Disease and other conditions related to defects in the APP pathway. The patent includes pharmaceutical compositions comprising substances directed toward these genes.
Career Highlights
Alyce Lynn Finelli is currently associated with Novartis Corporation, where she continues her research and development efforts. Her work has been instrumental in advancing the understanding of Alzheimer's Disease and exploring new therapeutic avenues.
Collaborations
Some of her notable coworkers include Dalia Cohen and Uwe Jochen Dengler, who collaborate with her on various research projects.
Conclusion
Alyce Lynn Finelli's contributions to Alzheimer's research through her innovative patent and work at Novartis Corporation highlight her role as a key figure in the scientific community. Her efforts are paving the way for potential breakthroughs in the treatment of Alzheimer's Disease.